Dengzhan Xixin Mixture

1. Effects on the cardiovascular system 0.25mg/ml.smg/ml of Erigeron breviscapus extract can significantly enhance the coronary flow of isolated guinea pig hearts [1]. 4mg (extract)/ml of Erigeron breviscapus water-soluble fraction can relax the contracted pig coronary arteries caused by 15-methyl prostaglandin FZα [2]. Erigeron breviscapus can significantly reduce the range of myocardial infarction in canine myocardial infarction models. Electron microscopic observation showed that the degree of lesions in the central and marginal areas of the infarct in the animals in the drug-treated groups was reduced. Observation of coronary vascular tree casting showed that Erigeron breviscapus injection may promote the opening of coronary collateral circulation. Anesthetized large bolus injection of Erigeron breviscapus injection of 10mg/kg has the effects of slowing down heart rate, reducing myocardial contractility, reducing myocardial oxygen consumption and work [3]. In the rat whole heart hypoxia and reoxygenation model, the release of cardiac creatine phosphokinase was significantly reduced in the group perfused with 100mg/L of Erigeron breviscapus total flavonoids; after reoxygenation, the release amplitude was also significantly lower than that of the control group, indicating that Erigeron breviscapus has a protective effect on cardiac cell membranes. After 50 minutes of simple hypoxic perfusion, the myocardium of the drug-treated group showed higher superoxide dismutase and glutathione peroxidase activities. After 5 minutes of reoxygenation, the myocardial malonate level of the drug-treated group was significantly lower than that of the control group [4]. Erigeron flavonoids caused a downward trend in aortic blood flow and heart rate in rabbits, but had no significant effect on blood pressure [5]. The total effective rate of oral Erigeron capsules in the clinical treatment of angina pectoris caused by coronary heart disease was higher than that of Salvia miltiorrhiza. The patients' heart function indicators such as stroke volume, stroke volume per minute, and cardiac index were improved [6]. Erigeron flavonoids also have an antagonistic effect on myocardial ischemia and hypoxic ECG changes [7]. 2 Anticoagulant, antithrombotic and fibrinolytic activity Erigeron flavonoids at a concentration of 23 mg/ml had an in vitro inhibition rate of 56.5% on rabbit platelet aggregation [1]. The injection of Erigeron breviscapus (containing Erigeron breviscapus flavonoids smg/l) was intravenously injected into rabbits at 8ml/kg. After 1h and 2h of administration, the peripheral platelet count decreased, the platelet aggregation function decreased, and substantial changes occurred [18]. The drug effect reached its peak 2h after administration. At 1h, 2h, and 4h after injection, the partial thromboplastin time of white clay was prolonged, while the prothrombin time did not change significantly. 1h after injection, plasma fibrinogen decreased, globulin lysis time decreased, and serum fibrinogen degradation products increased, indicating that Erigeron breviscapus has the effect of promoting fibrinolytic activity. After 2h of intravenous administration to rabbits, the in vitro thrombosis time was prolonged, the length of the thrombus was shortened, and the wet and dry weight of the thrombus were reduced, indicating that Erigeron breviscapus can inhibit in vitro thrombosis, and the effect is strongest after administration 2h [8]. Intravenous injection of 140mg/kg and 350mg/g of breviscapine can significantly reduce the weight of thrombus in rabbits with aortic thrombosis model and inhibit thrombus formation. This effect is positively correlated with the dose. Breviscapine can also reduce the degree of platelet rupture and inhibit the enhancement of 5-hydroxytryptamine release reaction. There was no significant change in the arachidonic acid metabolite thromboxane B2 (TXB2) and 6-keto-PGF1α in platelets and vascular endothelial cells in the treatment group, while it increased significantly in the control group [9]. Breviscapine gum has an inhibitory effect on platelet aggregation rate and in vitro thrombus formation in patients with angina pectoris of coronary heart disease [6]. 3. Effects on microcirculation and blood rheology In the models of rabbit cerebral microcirculation disorder caused by high molecular weight dextran and guinea pig soft brain microcirculation disorder, intravenous injection of breviscapine extract can significantly restore the rabbit cerebral cortex electroencephalogram, improve the microvascular flow state of guinea pig pia mater, have a significant depolymerization effect on guinea pig red blood cells, and counteract the vasoconstriction effect of norepinephrine [1-12]. For rat mesenteric microcirculatory disorders caused by dextran, pre-intravenous injection of Erigeron breviscapus extract, or administration of the same dose and method after modeling, significantly promoted microvascular opening and improved microcirculation. They can also counteract the vasoconstrictive effect of adrenaline [10, 13]. Intravenous injection of 10 ml/kg of Erigeron breviscapus injection can improve the microcirculatory state of rabbits with microcirculatory disorders caused by high-molecular-weight dextran, as shown by the restoration of flow in capillaries or venules and the acceleration of flow rate. In addition, whole blood (specific) viscosity, plasma (specific) viscosity, red cell electrophoresis and platelet electrophoresis have all recovered [14]. Rabbits were intravenously injected with 20 mg/kg of Erigeron breviscapus injection, and the whole blood viscosity decreased significantly; daily intramuscular injection of 10 mg/kg for 14 consecutive days, and blood samples were taken on the 3rd and 7th days after injection, and the whole blood viscosity also decreased significantly. However, there was no significant change in plasma viscosity [15]. 4. Cerebral vasodilatory effect When rabbits were intravenously injected with 5% 1g/kg of scutellaria brevis extract, the cerebral vascular tension, peripheral vascular resistance and peripheral blood pressure of the rabbits were significantly reduced [1]. 5X10-g/ml of scutellaria brevis flavonoids had a significant dilating effect on the isolated middle cerebral artery of dogs, and significantly resisted the effects of 5-hydroxytryptamine on the constriction of the basilar artery and 15-methylprostaglandin F2a on the constriction of the middle cerebral artery. Scutellaria brevis had no significant effect on the flow of vertebral arteries in anesthetized dogs [5]. 5. Other effects When mice were intraperitoneally injected with 20mg/kg of scutellaria brevis extract, the plasma cAMP content gradually increased within 5min and reached a peak at 20min. It showed a dose-response relationship within the dose range of 1mg/kg to 20mg/kg, and mg/kg was the maximum effective dose [16]. 60g (raw drug)/kg of 20% scutellaria brevis extract aqueous solution was given to mice by gavage, which significantly prolonged the survival time of mice in normobaric hypoxia [1]. Baicalin from alpine has an inhibitory effect on protein kinase C (PKC), with an IC50 of 48pmol/L. Baicalin from alpine showed an inhibitory effect on PKC at a2± concentration of 10-2 to 10-7mol/L. This effect was not reversed by the increase in the concentration of dioleylglycerol or substrate histone, indicating that the inhibitory effect of baicalin from alpine belongs to non-competitive inhibition [17]. Brevibacterium breviscapus preparations can also improve the permeability of the blood-brain barrier, counteract platelet aggregation caused by diphosphate adenosine, and improve the body's macrophage phagocytic immune function [18]. 6. In vivo process After intravenous injection of 10mg/kg of 3H-breviscapus acetone in mice, the 3H content in the blood showed a rapid downward trend within 60min. After intravenous injection for 1h, 3H-breviscapus acetone was distributed more in the gallbladder, small intestine, liver, and kidney; after 4h, it was more in the gallbladder, small intestine, liver, and myocardium, and the distribution in the brain was also significantly increased. After 24h, there was still a certain amount of radioactivity in the gallbladder, small intestine, and brain. After intravenous injection of 3H-scutellarin into mice, the total amount excreted in urine for 24 hours was 19.1% of the injected amount, and the total amount excreted in feces for 24 hours was 24.1% of the injected amount [19]. 7. Toxicity After oral administration of 0.4 ml/kg of 20% scutellaria brevis extract aqueous solution (equivalent to 80 g/kg of crude drug) to male mice, no death was observed for 3 days. Male mice were intraperitoneally injected with 5% scutellaria brevis extract solution, and the LD50 was measured by simplified probability unit method. It was 13.14 ± 5.42 g/kg, and the LD50 of intravenous injection was 10.02 ± 1.55 g/kg [1]. Subacute toxicity tests have shown that scutellarin has no effect on blood counts, liver and kidney functions, and no substantial changes in internal organs [18].

Erigeron breviscapus extract.

mixture

Oral administration, 10-20 ml at a time, 3 times a day.

Occasionally stomach upset.

It is contraindicated for those who are allergic to this product.

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Sealed, store in a dry place.

Each bottle contains 10 ml, containing 70 mg of total flavonoids; each bottle contains 100 ml, containing 700 mg of total flavonoids

18 months

Yunnan Phyto Pharmaceutical Co., Ltd.

• Founded in:

  1998-10-26

• Address:

  No. 2899, Macheng Road, Majinpu, High-tech Zone, Kunming City, Yunnan Province

• Tax NO.:

  915300007097131980

• Registered Funds:

  131.12 million yuan

• Website:

  Log in to view

• Email:

  Log in to view